Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Notch inhibitor

DRUG CLASS:

Notch inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	RG4733 Sensitive: C2 – Inclusion Criteria RG4733 Sensitive : C2	RG4733 Sensitive: C2 – Inclusion Criteria RG4733 Sensitive : C2
NOTCH mutation	Adenoid Cystic Carcinoma	NOTCH mutation	Adenoid Cystic Carcinoma	AL101 Sensitive: C3 – Early Trials AL101 Sensitive : C3	AL101 Sensitive: C3 – Early Trials AL101 Sensitive : C3
EGFR C797S	Lung Adenocarcinoma	EGFR C797S	Lung Adenocarcinoma	Notch inhibitor + osimertinib Sensitive: D – Preclinical Notch inhibitor + osimertinib Sensitive : D	Notch inhibitor + osimertinib Sensitive: D – Preclinical Notch inhibitor + osimertinib Sensitive : D
NOTCH1 amplification	Colorectal Cancer	NOTCH1 amplification	Colorectal Cancer	PF‐06293622 Sensitive: D – Preclinical PF‐06293622 Sensitive : D	PF‐06293622 Sensitive: D – Preclinical PF‐06293622 Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	niclosamide Sensitive: D – Preclinical niclosamide Sensitive : D	niclosamide Sensitive: D – Preclinical niclosamide Sensitive : D
ER Y537S	Breast Cancer	ER Y537S	Breast Cancer	CB-103 Sensitive: D – Preclinical CB-103 Sensitive : D	CB-103 Sensitive: D – Preclinical CB-103 Sensitive : D